Description
Labcorp’s BIGGEST Pressure Point Is 13.5% Early Development Decline
Labcorp Holdings reported strong financial performance for the fourth quarter and full year 2025, with notable advancements across various strategic priorities. The company saw revenue growth of over 7% for the year, with adjusted earnings per share (EPS) increasing by 13% and margins expanding by more than 50 basis points. The fourth quarter revenue increased 6%, with adjusted EPS up 18%, indicating robust performance. These results were supported by solid achievements in both the Diagnostics and Biopharma Laboratory Services (BLS) segments. A key highlight was the successful integration of acquisitions and strategic initiatives, such as signing or closing 13 new partnerships with health systems and laboratories. This contributed to over $1 billion in revenue growth. The acquisition of outreach laboratory services from Parkview Health and other assets illustrates Labcorp’s focus on expanding its reach and portfolio in routine and specialty testing.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
